MINIREVIEW: Perspectives on plasmid‐based gene therapy: challenges for the product and the process
- 1 June 2003
- journal article
- review article
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 37 (3), 219-223
- https://doi.org/10.1042/ba20030033
Abstract
Clinical trials for gene-therapy products began in the 1990s. Currently, most of the 630 completed or on-going trials are in Phase I and II. Because of the safety issues surrounding the use of viral vectors, approx. 25% of the ongoing clinical trials use DNA plasmids to carry the corrective gene (http://www.wiley.co.uk/genmed). The purpose of this perspective (and this issue) is to highlight some of the unique technical challenges and potential solutions associated with the manufacture and expression of a plasmid-based gene-therapy product.Keywords
This publication has 38 references indexed in Scilit:
- Fractional precipitation of plasmid DNA from lysate by CTABBiotechnology & Bioengineering, 2002
- Purification of plasmid DNA by an integrated operation comprising tangential flow filtration and nitrocellulose adsorptionBiotechnology & Bioengineering, 2002
- Clinical Trials of HIV VaccinesAnnual Review of Medicine, 2002
- Downstream processing of plasmid DNA for gene therapy and DNA vaccine applicationsTrends in Biotechnology, 2000
- Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecksTrends in Biotechnology, 1999
- Effect of shear on plasmid DNA in solutionBioprocess and Biosystems Engineering, 1999
- Examination of Parameters Affecting the Elicitation of Humoral Immune Responses by Particle Bombardment-Mediated Genetic ImmunizationDNA and Cell Biology, 1993
- In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient DogsScience, 1993
- Analysis of pBR322 replication kinetics and its dependency on growth rateBiotechnology & Bioengineering, 1990
- Escherichia coli plasmid production in fermenterBiotechnology & Bioengineering, 1989